Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Galiz Research

Neither a doctor nor a teaching hospital

Research payments

$2,635,620

206 payments

Through program year 2025, Galiz Research is reported as receiving $2,635,620 in research payments, across 206 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $105,719 118
2024 Research $100,748 5
2023 Research $5,634 2
2022 Research $138,878 6
2021 Research $404,929 22
2020 Research $530,649 21
2019 Research $1,349,064 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,710,577 27 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $311,013 5 payments
  3. Boehringer Ingelheim International GmbH $196,997 120 payments
  4. Eli Lilly and Company $195,989 4 payments
  5. ACADIA Pharmaceuticals Inc $123,578 26 payments
  6. Avanir Pharmaceuticals, Inc. $55,845 13 payments
  7. Alkermes, Inc. $21,000 3 payments
  8. Eisai Inc. $19,548 5 payments
  9. AbbVie, Inc. $962 1 payment
  10. Merck Sharp & Dohme Corporation $62 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Protocol 331-201-00080 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $413,941 1 payment
  2. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $409,724 1 payment
  3. PoCC dose finding in Mild to Moderate AD $300,976 3 payments
  4. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $162,677 2 payments
  5. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $115,229 2 payments
  6. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $112,165 2 payments
  7. A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of Azd3293 in Early Alzheimers Disease -The Amaranth Study $104,538 1 payment
  8. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease Ad Geras US $91,447 2 payments
  9. Phase II DRF study of NR2B modulation in MDD $91,278 2 payments
  10. A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder $90,891 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record